Theravance Biopharma: Hold Rating Amid Financial Challenges and Study Uncertainties

Analyst David Risinger of Leerink Partners maintained a Hold rating on Theravance Biopharma (TBPH – Research Report), retaining the price target of $10.00.

David Risinger has given his Hold rating due to a combination of factors impacting Theravance Biopharma’s financial performance and future prospects. The company’s first-quarter revenue and earnings per share fell short of market expectations, primarily due to higher operating expenses. Although the company maintained its full-year operating expense guidance, the seasonal nature of its earnings suggests a cautious approach.
Furthermore, the slight delay in the ampreloxetine Cypress study’s timeline and the associated uncertainty contribute to the Hold rating. While the company is confident in managing tariff risks and does not foresee significant impacts, the outcome of the Cypress study remains a critical factor. The potential for a New Drug Application submission and priority review hinges on positive Phase 3 data, adding to the uncertainty. These elements collectively justify the Hold rating on TBPH shares.

In another report released on May 9, TD Cowen also maintained a Hold rating on the stock with a $12.00 price target.

TBPH’s price has also changed moderately for the past six months – from $8.940 to $9.900, which is a 10.74% increase.